ARIMIDEX® (anastrozole) Tablets Savings Card Provides Instant Savings to Eligible Patients

WILMINGTON, Del., July 1 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced a new patient support program for postmenopausal women with hormone receptor-positive early breast cancer who are prescribed ARIMIDEX. The program is designed to provide eligible patients with instant discounts, potentially saving the patient up to $300.

(Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO )

When using the ARIMIDEX Savings Card, patients with prescription coverage and copay of more than $50 can get up to $50 in instant savings*, up to a maximum of 6 times, each time they fill an ARIMIDEX prescription.  

Examples of Savings for ARIMIDEX

Prescription Copay

Patient Pays

AstraZeneca Pays

$50

$50

N/A

$75

$50

$25

$100

$50

$50



The process to receive an ARIMIDEX Savings Card entails no paperwork for patients. Patients can contact their health care provider and then check eligibility requirements by calling the AstraZeneca Information Center at 1-800-236-9933, Monday to Friday from 8 AM to 6 PM ET, excluding holidays. If eligible, patients can obtain an ARIMIDEX Savings Card from their health care provider or from the AstraZeneca Information Center. In addition, by the end of July, patients will be able to download the ARIMIDEX Savings Card on www.inyourcorner.com. Patients should present their ARIMIDEX Savings Card to a participating pharmacist, along with their prescription and insurance card, and they may receive instant savings, up to $50 per fill, up to six fills.

*Eligibility: This offer is good for qualified customers for the purchase of a 30-day supply of ARIMIDEX and may not be used for any other product. This offer is good for the purchase of ARIMIDEX distributed by AstraZeneca LP or AstraZeneca Pharmaceuticals LP and lawfully purchased from an authorized retailer in the United States or its territories. This offer may not be combined with any other offer, including any coupon, discount, or prescription savings card program. It is void for mail order and is not valid for prescriptions purchased under Medicaid, Medicare, or similar state or federally funded healthcare programs and is void where prohibited by law, taxed, or restricted. Not valid for residents of MA, PR and VI. At time of purchase, present card along with a valid prescription for ARIMIDEX to receive your savings. If you have prescription coverage and your copay is more than $50, you may receive up to $50 in savings on each fill for ARIMIDEX up to 6 fills. Offer is limited to one savings card per person. Offer good only in the United States. Program sponsors reserve the right to discontinue this offer at any time.

Important Information About ARIMIDEX

ARIMIDEX is approved for adjuvant treatment (treatment following surgery with or without radiation) of postmenopausal women with hormone receptor-positive early breast cancer.

ARIMIDEX is approved for the initial treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of postmenopausal women with advanced breast cancer that has progressed following treatment with tamoxifen. Patients with hormone receptor-negative disease and patients who did not previously respond to tamoxifen therapy rarely responded to ARIMIDEX.

Important Safety Information About ARIMIDEX

  • Prescription ARIMIDEX is only for postmenopausal women. ARIMIDEX should not be taken if you are pregnant because it may harm your unborn child
  • Based on information from a study in patients with early breast cancer, women with a history of blockages in heart arteries (ischemic heart disease) who take ARIMIDEX may have a slight increase in this type of heart disease compared to similar patients who take tamoxifen

Please see additional Important Safety Information on the next page.

Additional Important Safety Information About ARIMIDEX

  • ARIMIDEX can cause bone softening/weakening (osteoporosis) increasing the chance of fractures. In a clinical study in early breast cancer, there were more fractures (including fractures of the spine, hip, and wrist) with ARIMIDEX (10%) than with tamoxifen (7%)
  • In a clinical study in early breast cancer, some patients taking ARIMIDEX had an increase in cholesterol. Skin reactions, allergic reactions, and changes in blood tests of liver function have also been reported
  • In the early breast cancer clinical trial, the most common side effects seen with ARIMIDEX include hot flashes, joint symptoms (including arthritis and arthralgia), weakness, mood changes, pain, back pain, sore throat, nausea and vomiting, rash, depression, high blood pressure, osteoporosis, fractures, swelling of arms/legs, insomnia, and headache
  • In advanced breast cancer trials, the most common side effects seen with ARIMIDEX versus tamoxifen include hot flashes, nausea, decreased energy and weakness, pain, back pain, headache, bone pain, increased cough, shortness of breath, sore throat, and swelling of arms and legs. Joint pain/stiffness has been reported in association with the use of ARIMIDEX
  • ARIMIDEX should not be taken with tamoxifen or estrogen-containing therapies

Please click here for full prescribing information.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business.

For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).

SOURCE AstraZeneca

Suggested Articles

The Federal Trade Commission issued orders to five health insurance companies and two health systems seeking data to study the effects of COPAs.

An influential group of Republican lawmakers released its latest healthcare plan, which closely resembles prior Affordable Care Act repeal efforts.

An ACA public option could lead to lower premiums for commercial plans by sparking more competition, an analysis found.